Novo Nordisk has a range of products relating to diabetes, haemostasis, obesity, growth and the menopause. Downloads of the Product Information for these products are available in this section.
Written principally for Healthcare Professionals, the Product Information documents provide prescribing information for each of our products. If you are not a Healthcare Professional, Product Information should be read/discussed in consultation with a Healthcare Professional.
To view these files you need to have Adobe Acrobat Reader installed. If you do not have Adobe Acrobat Reader you can download the software free of charge. Get Acrobat Reader
Novo Nordisk has advised the TGA there will be continued, limited intermittent availability in Australia of Ozempic® (semaglutide), a medicine approved for use in adults with type 2 diabetes, until December 2024.
The reason for the extended intermittent availability is the
continued, unprecedented strong demand for Ozempic®
(semaglutide) in Australia and around the world.
Whilst Ozempic® (semaglutide) supply in Australia
improved significantly in 2023, there continues to be strong
demand.
Novo Nordisk is working hard to satisfy demand to the greatest extent possible. Our deliveries of Ozempic® (semaglutide) to Australia in 2023 were significantly more than compared to 2022
Novo Nordisk continues to expand its global manufacturing
capacity to meet the strong demand for Ozempic®
(semaglutide) for now and into the future. Our global manufacturing
facilities are running 24 hours a day, seven days a week. By the end
of 2023, we will have invested more than $US5B in the past two years
to open new production lines and facilities.
Novo Nordisk, the TGA, AMA, RACGP, Pharmacy Guild and
organisations representing diabetes and obesity will continue to
work together and will continue to monitor the situation, and
provide updated guidance as required
It’s important to continue to follow the joint guidance issued by the TGA and various professional bodies on this matter, and additional information about Ozempic® (semaglutide) supply on the TGA website. Novo Nordisk has and will continue to work with the TGA on providing updates on this matter.